High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma

Diagn Pathol. 2022 Dec 31;17(1):100. doi: 10.1186/s13000-022-01274-9.

Abstract

Clear cell renal cell carcinoma (ccRCC) is a growing public health challenge worldwide. Hepcidin antimicrobial peptide (HAMP) is differentially expressed in various tumors. However, the roles and functions of HAMP in ccRCC remain unclear. In the present study, we integrated systematic bioinformatics approaches to investigate the roles and functions of HAMP and its association with immune cell infiltration in ccRCC. Compared with paracancerous tissue, HAMP expression was significantly upregulated in ccRCC patients. Meanwhile, we found good diagnostic performance of HAMP for ccRCC patients and its close associations with the clinicopathological features of ccRCC patients. In addition, we found that HAMP is closely related to multiple immune pathways and positively correlated with various immune cells. HAMP was a significant independent predictor for ccRCC. High expression of HAMP was associated with worse clinical prognosis and more immune cell infiltration in ccRCC patients. HAMP may offer potential as a biomarker to predict prognosis and the clinical treatment outcome of ccRCC patients.

Keywords: Bioinformatics analysis; Clear cell renal cell carcinoma; HAMP; Immune cell infiltration; Prognosis.

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma*
  • Carcinoma, Renal Cell*
  • Computational Biology
  • Hepcidins
  • Humans
  • Kidney Neoplasms*
  • Prognosis

Substances

  • Hepcidins
  • Biomarkers, Tumor